Cancerous disease modifying antibodies
US7252821B2 · kind B2 · utility
5Cited by
14References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 23, 2003 |
| Grant date | Aug 7, 2007 |
| Priority date | — |
| Expiry date | Dec 5, 2024 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/505
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.